NASDAQ:ARLZ - Aralez Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.39 -0.01 (-2.50 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$0.39
Today's Range$0.39 - $0.41
52-Week Range$0.36 - $2.98
Volume582,300 shs
Average Volume1.04 million shs
Market Capitalization$26.88 million
P/E Ratio-0.33
Dividend YieldN/A
Beta1.39
Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.

Receive ARLZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARLZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ARLZ
CUSIP73941U10
Phone905-876-1118

Debt

Debt-to-Equity Ratio-41.79
Current Ratio0.80
Quick Ratio0.75

Price-To-Earnings

Trailing P/E Ratio-0.33
Forward P/E Ratio-0.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$105.95 million
Price / Sales0.25
Cash FlowN/A
Price / CashN/A
Book Value$0.23 per share
Price / Book1.70

Profitability

EPS (Most Recent Fiscal Year)($1.20)
Net Income$-125,200,000.00
Net Margins-99.50%
Return on Equity-271.44%
Return on Assets-20.46%

Miscellaneous

Employees164
Outstanding Shares67,190,000

The Truth About Cryptocurrencies

Aralez Pharmaceuticals (NASDAQ:ARLZ) Frequently Asked Questions

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) released its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.04. The company had revenue of $38.08 million for the quarter, compared to analyst estimates of $31.40 million. Aralez Pharmaceuticals had a negative return on equity of 271.44% and a negative net margin of 99.50%. View Aralez Pharmaceuticals' Earnings History.

When is Aralez Pharmaceuticals' next earnings date?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Aralez Pharmaceuticals.

What price target have analysts set for ARLZ?

3 equities research analysts have issued 12-month target prices for Aralez Pharmaceuticals' stock. Their predictions range from $4.00 to $6.00. On average, they expect Aralez Pharmaceuticals' share price to reach $5.00 in the next twelve months. View Analyst Ratings for Aralez Pharmaceuticals.

Who are some of Aralez Pharmaceuticals' key competitors?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:
  • Mr. Adrian Adams, CEO & Director (Age 67)
  • Mr. Andrew I. Koven, Pres & Chief Bus. Officer (Age 60)
  • Dr. James Patrick Tursi, Chief Medical Officer (Age 53)
  • Mr. Michael Kaseta, Chief Financial Officer (Age 42)
  • Mr. John E. Barnhardt CPA, Principal Accounting Officer and VP of Fin. & Admin. (Age 68)

Has Aralez Pharmaceuticals been receiving favorable news coverage?

News articles about ARLZ stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Aralez Pharmaceuticals earned a coverage optimism score of 0.08 on Accern's scale. They also gave media coverage about the company an impact score of 46.45 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Aralez Pharmaceuticals' major shareholders?

Aralez Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Wells Fargo & Company MN (1.52%), GSA Capital Partners LLP (0.39%) and Salzhauer Michael (0.33%). Company insiders that own Aralez Pharmaceuticals stock include Adrian Adams, Andrew I Koven, Arthur S Kirsch, Eric Trachtenberg, James Patrick Tursi, Jason Aryeh, Kenneth B Lee Jr, Mark A Glickman, Robert Paul Harris, Scott J Charles and Seth Rudnick. View Institutional Ownership Trends for Aralez Pharmaceuticals.

Which institutional investors are selling Aralez Pharmaceuticals stock?

ARLZ stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP. Company insiders that have sold Aralez Pharmaceuticals company stock in the last year include Andrew I Koven, James Patrick Tursi, Mark A Glickman and Scott J Charles. View Insider Buying and Selling for Aralez Pharmaceuticals.

Which institutional investors are buying Aralez Pharmaceuticals stock?

ARLZ stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN and Salzhauer Michael. Company insiders that have bought Aralez Pharmaceuticals stock in the last two years include Adrian Adams, Arthur S Kirsch, James Patrick Tursi, Kenneth B Lee Jr and Seth Rudnick. View Insider Buying and Selling for Aralez Pharmaceuticals.

How do I buy shares of Aralez Pharmaceuticals?

Shares of ARLZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aralez Pharmaceuticals' stock price today?

One share of ARLZ stock can currently be purchased for approximately $0.39.

How big of a company is Aralez Pharmaceuticals?

Aralez Pharmaceuticals has a market capitalization of $26.88 million and generates $105.95 million in revenue each year. The company earns $-125,200,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Aralez Pharmaceuticals employs 164 workers across the globe.

How can I contact Aralez Pharmaceuticals?

Aralez Pharmaceuticals' mailing address is 7100 WEST CREDIT AVENUE SUITE 101, MISSISSAUGA A6, L5N 0E4. The company can be reached via phone at 905-876-1118 or via email at [email protected]


MarketBeat Community Rating for Aralez Pharmaceuticals (ARLZ)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARLZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARLZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.